TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24954491

Group type: EXPERIMENTAL
Intervention: Fast-track surgery for THA and TKA
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Age as an independent predictor
Number of subjects: 153
Study: 24954791

Group type: EXPERIMENTAL
Intervention: Degarelix (240mg starting dose, then 80mg once a month for 6 months)
Number of subjects: 213
Study: 24956535

Group type: EXPERIMENTAL
Intervention: RBP4 levels in HGCS (51.44 ± 16.23 mg/L)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Omentin-1 levels in HGCS (490.41 ± 172 ng/ml)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: RBP4 and hsCRP as independent determinants of TPA
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Low serum levels of omentin-1
Number of subjects: 225
Study: 24957163

Group type: EXPERIMENTAL
Intervention: CCRT (two cycles of the DEP regimen every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Consolidation DVIP (two cycles every 4 wk after CCRT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CCRT plus consolidation chemotherapy
Number of subjects: 62
Study: 24957314

Group type: EXPERIMENTAL
Intervention: IV-TPA (3-4.5 hours)
Number of subjects: 723
Study: 24957534

Group type: EXPERIMENTAL
Intervention: Mifepristone (200mg) followed by Misoprostol (800μg buccal)
Number of subjects: 1000
Study: 24957547

Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 737

Group type: COMPARATOR
Intervention: Control
Number of subjects: 737
Study: 24958581

Group type: EXPERIMENTAL
Intervention: Cognitive impairment and mental health disorders assessment
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 73
Study: 24958808

Group type: EXPERIMENTAL
Intervention: Single dose of zoledronic acid
Number of subjects: 29
Study: 24960254

Group type: EXPERIMENTAL
Intervention: mGluR5 negative allosteric modulators (NAMs) coadministered with L-DOPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-DOPA
Number of subjects: 0
Study: 24960544

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (10,000 IU weekly)
Number of subjects: 66
Study: 24961159

Group type: EXPERIMENTAL
Intervention: Change in Social Affect (SA) calibrated severity score
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nonverbal cognitive ability
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ADOS overall level of language item
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Change in Restricted and Repetitive Behaviors (RRB) severity score
Number of subjects: 70
Study: 24961662

Group type: EXPERIMENTAL
Intervention: Simeprevir (TMC435) 100 mg once daily with PEG IFN-α-2b/RBV
Number of subjects: 79
Study: 24961747

Group type: EXPERIMENTAL
Intervention: H1N1 vaccine
Number of subjects: 78
Study: 24962156

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (CMR) parameters including infarct size, microvascular obstruction (MO), myocardial salvage index (MSI), and left ventricular ejection fraction (LV-EFCMR).
Number of subjects: 278

Group type: COMPARATOR
Intervention: Traditional outcome markers including ST-segment resolution, pre- and post-PCI TIMI-flow, maximum level of creatine kinase-MB, TIMI-risk score, and left ventricular ejection fraction assessed by echocardiography.
Number of subjects: 278
Study: 24962750

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib+HBV
Number of subjects: 185
Study: 24963042

Group type: EXPERIMENTAL
Intervention: Fludarabine/melphalan (FluMel) as a preparative regimen for sibling donors
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fludarabine/melphalan (FluMel) plus anti-thymocyte globulin (ATG) for unrelated donors
Number of subjects: 66
Study: 24963043

Group type: EXPERIMENTAL
Intervention: Carfilzomib 56 mg/m2
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Carfilzomib 56 mg/m2 + Dexamethasone (20 mg)
Number of subjects: 44
Study: 24963112

Group type: EXPERIMENTAL
Intervention: Serum levels of PCB153
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sum of PCBs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p,p'-DDE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adipose tissue levels of p,p'-DDE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum levels of PCBs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum and adipose tissue levels of all POPs
Number of subjects: 0
Study: 24963497

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine-based chemoimmunotherapy
Number of subjects: 0
Study: 24964010

Group type: EXPERIMENTAL
Intervention: 3-min break after 30 SED min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6-min break after 60 SED min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 12-min break after 120 SED min
Number of subjects: 30
Study: 24964084

Group type: EXPERIMENTAL
Intervention: EV71-C4a vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New pseudovirus-based neutralization assay
Number of subjects: 0
Study: 24964317

Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CT Colonography (CTC)
Number of subjects: 100
Study: 24964817

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: (123)I-mIBG scintigraphy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Follow-up (18)F-FDG PET
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Follow-up (123)I-mIBG scintigraphy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Initial altered cardiac metabolism
Number of subjects: 30
Study: 24964991

Group type: EXPERIMENTAL
Intervention: Single-culture virus-specific T cells (VSTs) targeting 12 immunogenic antigens from five viruses (AdV, EBV, CMV, BKV, HHV6)
Number of subjects: 11
Study: 24965302

Group type: EXPERIMENTAL
Intervention: Plasma di-homo-γ-linolenic acid
Number of subjects: 51
Study: 24965748

Group type: EXPERIMENTAL
Intervention: Orteronel 300 mg twice daily until PSA progression, metastases, or unacceptable toxicity.
Number of subjects: 39
Study: 24965999

Group type: EXPERIMENTAL
Intervention: Unilateral laparoscopic ovarian drilling with thermal doses adjusted to ovarian volume: median of 720J (IQR)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bilateral drilling with fixed doses of 1200J
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both interventions (unilateral and bilateral diathermy)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Baseline value of T
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Value of T in the 1st month after diathermy
Number of subjects: 96
Study: 24966061

Group type: EXPERIMENTAL
Intervention: ELLIPTA dry powder inhaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24966411

Group type: EXPERIMENTAL
Intervention: Phytase added to maize porridge immediately before consumption or used for dephytinization during meal preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Na2EDTA at an EDTA:zinc molar ratio of 1:1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (ZnSO4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorghum polyphenols
Number of subjects: 0
Study: 24967217

Group type: EXPERIMENTAL
Intervention: Rotavirus gastroenteritis (RVGE) hospitalizations
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Rotavirus gastroenteritis (RVGE) ER visits
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Community-acquired AGE cases due to RV
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Incidence of nosocomial RVGE
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Median duration of hospitalization among RV-positive subjects
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Median duration for additional hospitalization due to nosocomial RVGE
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Burden of nosocomial RVGE in children aged 12-23 months
Number of subjects: 1222
Study: 24967244

Group type: EXPERIMENTAL
Intervention: Living kidney donation
Number of subjects: 81
Study: 24969309

Group type: COMPARATOR
Intervention: Placebo group (n=72)
Number of subjects: 180
Study: 24969506

Group type: EXPERIMENTAL
Intervention: Aspirin within 24 hours
Number of subjects: 12264

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12264

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 12264

Group type: COMPARATOR
Intervention: Proportion of patients who did not receive reperfusion
Number of subjects: 12264

Group type: EXPERIMENTAL
Intervention: Median length of hospital stay
Number of subjects: 12264

Group type: COMPARATOR
Intervention: Adjusted in-hospital mortality
Number of subjects: 12264
Study: 24969516

Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate, 50 mg/d for 24 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 33
Study: 24969797

Group type: EXPERIMENTAL
Intervention: Postoperative hyperfractionated radiation therapy (36 Gy to craniospinal axis, 68 Gy to tumor region, 72 Gy to residual tumor, fractionated at 2 × 1 Gy per day 5 days per week) followed by maintenance chemotherapy (lomustine, cisplatin, and vincristine)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Postoperative hyperfractionated radiation therapy followed by maintenance chemotherapy
Number of subjects: 26
Study: 24970095

Group type: EXPERIMENTAL
Intervention: Remote grading of images by trained nonphysician readers
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Remote grading of images considering both eyes
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Criterion standard diagnostic examination
Number of subjects: 1257
Study: 24970468

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study: 24970686

Group type: EXPERIMENTAL
Intervention: 3% saline infusion
Number of subjects: 23
Study: 24970773

Group type: EXPERIMENTAL
Intervention: Escitalopram, sertraline, or extended-release venlafaxine (8-week course)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Matched controls (no specific intervention mentioned)
Number of subjects: 102
Study: 24970782

Group type: EXPERIMENTAL
Intervention: Extended-duration rivaroxaban
Number of subjects: 2593

Group type: COMPARATOR
Intervention: Standard-duration enoxaparin followed by placebo
Number of subjects: 2593
Study: 24970846

Group type: EXPERIMENTAL
Intervention: CPS-immunization with Plasmodium falciparum sporozoites
Number of subjects: 38
Study: 24970906

Group type: EXPERIMENTAL
Intervention: FBB+ (positive FBB defined by SUVR ≥ 1.45)
Number of subjects: 45

Group type: COMPARATOR
Intervention: FBB- (negative FBB)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hippocampal volume (HV)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Amnestic MCI (aMCI) status
Number of subjects: 45
Study: 24970932

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*07:01 alleles
Number of subjects: 1870

Group type: EXPERIMENTAL
Intervention: HLA-DRB1 alleles predicted high-affinity binding
Number of subjects: 1870
Study: 24972362

Group type: EXPERIMENTAL
Intervention: Tranylcypromine up to 60 mg/d
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tranylcypromine up to 120 mg/d
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine added to tranylcypromine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nortriptyline + lithium
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Phenelzine added to nortriptyline + lithium
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Maintenance of remission
Number of subjects: 28
Study: 24972632

Group type: EXPERIMENTAL
Intervention: Rice-lentil RUSF
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chickpea-based RUSF
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pushti packet (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rice-lentil RUSF and Chickpea-based RUSF
Number of subjects: 90
Study: 24973461

Group type: EXPERIMENTAL
Intervention: A/turkey/Turkey/1/2005(H5N1)-AS03B (booster vaccination)
Number of subjects: 113

Group type: COMPARATOR
Intervention: A/Indonesia/05/2005(H5N1)-AS03B (primary vaccination)
Number of subjects: 113
Study: 24973924

Group type: EXPERIMENTAL
Intervention: Saphenous Vein Y-composite graft (SV group, n = 112)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Right Internal Thoracic Artery Y-composite graft (RITA group, n = 112)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Saphenous Vein composite grafts
Number of subjects: 224

Group type: COMPARATOR
Intervention: Right Internal Thoracic Artery composite grafts
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Freedom from major adverse cardiac and cerebrovascular events
Number of subjects: 224
Study: 24974155

Group type: EXPERIMENTAL
Intervention: Prednisone 50 mg for 7 days
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 24974232

Group type: EXPERIMENTAL
Intervention: Continuous infusion of loop diuretics (furosemide)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Bolus treatment of loop diuretics (furosemide)
Number of subjects: 82
Study: 24974301

Group type: EXPERIMENTAL
Intervention: Triathlon™ posterior stabilised cemented knee prosthesis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Triathlon™ cruciate retaining cemented knee prosthesis
Number of subjects: 60
Study: 24974812

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phacoemulsification cataract surgery
Number of subjects: 0
Study: 24975234

Group type: EXPERIMENTAL
Intervention: Healthy dietary quality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reported noise exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interaction between dietary quality and reported noise exposure
Number of subjects: 0
Study: 24975273

Group type: EXPERIMENTAL
Intervention: Vitamin D₃ intervention
Number of subjects: 47
Study: 24975800

Group type: EXPERIMENTAL
Intervention: Mannitol bronchial challenge (PD15 < 635 mg)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Methacholine bronchial challenge (PC20 < 16 mg/mL)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Receiver operating curve analysis for mannitol
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Receiver operating curve analysis for methacholine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Correlation between log-transformed mannitol and methacholine response-dose ratios
Number of subjects: 104
Study: 24975809

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg daily for a mean of 10.0 days (range: 2.0 to 39.0 days)
Number of subjects: 2733

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg daily
Number of subjects: 2733
Study: 24976801

Group type: EXPERIMENTAL
Intervention: Community psychiatry program (including psychiatrist appointments, individual and group therapy, enhanced access to psychiatric medications) for 1 year
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Community psychiatry program
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Baseline cocaine and alcohol use disorder, current employment
Number of subjects: 156
Study: 24977398

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study: 24977639

Group type: EXPERIMENTAL
Intervention: Eleveld allometric PK model using total body weight (TBW)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adjusted body weight with Schnider and Marsh models
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3-compartment PK model linked to a sigmoidal inhibitory Emax PD model
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simulated effect-site target of 3.2 μg/mL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All tested PK models
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Traditional Schnider and Marsh models
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BIS response
Number of subjects: 20
Study: 24978650

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 24978858

Group type: EXPERIMENTAL
Intervention: Autologous islet transplantation (ITx)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral antidiabetic drugs (OAD)
Number of subjects: 19
Study: 24979126

Group type: EXPERIMENTAL
Intervention: Endolymphatic sac decompression surgery (ESDS)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Best available medical therapies (non-ESDS group)
Number of subjects: 67
Study: 24979313

Group type: EXPERIMENTAL
Intervention: Enhanced or standard CBT
Number of subjects: 94
Study: 24979445

Group type: EXPERIMENTAL
Intervention: Efavirenz-containing regimen
Number of subjects: 5332

Group type: COMPARATOR
Intervention: Efavirenz-free regimen
Number of subjects: 5332
Study: 24979578

Group type: EXPERIMENTAL
Intervention: Persistent depressive symptoms (Beck Depression Inventory score >10 at both times)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Patients without persistent depressive symptoms
Number of subjects: 251
Study: 24980678

Group type: EXPERIMENTAL
Intervention: Body image mediation
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Self-esteem mediation
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Sobel's test for body image
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Sobel's test for self-esteem
Number of subjects: 205
Study: 24980704

Group type: EXPERIMENTAL
Intervention: WHO criteria for GDM (fasting plasma glucose ≥ 7.0 mmol/L and/or 2-hour plasma glucose ≥ 7.8 mmol/L)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Simplified IADPSG criteria (fasting glucose ≥ 5.1 mmol/L and/or 2-h plasma glucose ≥ 8.5 mmol/L)
Number of subjects: 687
Study: 24981579

Group type: EXPERIMENTAL
Intervention: Group-based activities with on-site childcare and online support
Number of subjects: 36
Study: 24982357

Group type: EXPERIMENTAL
Intervention: Cytokine levels in tumor tissue (IL8, GM-CSF, VEGF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cytokine levels in serum (IL6)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cytokine levels correlated with TNM stage
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cytokine levels correlated with NLR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cytokine profiles in different tissues
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cytokine elevation reflects advanced disease
Number of subjects: 20
Study: 24982674

Group type: EXPERIMENTAL
Intervention: Personal-care dependency
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 296
Study: 24982681

Group type: EXPERIMENTAL
Intervention: Transdermal 17β estradiol (TBE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral 17β estradiol (OBE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral conjugated equine estrogen (OCEE)
Number of subjects: 20
Study: 24983020

Group type: EXPERIMENTAL
Intervention: Rapid HCV antibody testing
Number of subjects: 8500

Group type: COMPARATOR
Intervention: Current HCV screening recommendations
Number of subjects: 8500
Study: 24983206

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 1995

Group type: COMPARATOR
Intervention: Patients with comorbidities
Number of subjects: 1995

Group type: COMPARATOR
Intervention: Patients with methicillin-resistant Staphylococcus aureus
Number of subjects: 1995

Group type: COMPARATOR
Intervention: Patients requiring surgery
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: Modification of initial antibiotic treatment
Number of subjects: 1995
Study: 24983346

Group type: EXPERIMENTAL
Intervention: T1D-I (inadequate glycemic control)
Number of subjects: 35

Group type: COMPARATOR
Intervention: T1D-A (adequate glycemic control)
Number of subjects: 35

Group type: COMPARATOR
Intervention: CON-I (healthy controls)
Number of subjects: 35
Study: 24983357

Group type: EXPERIMENTAL
Intervention: BRAF inhibitor (vemurafenib or dabrafenib/trametinib combination)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: BRAF inhibitor (PLX4720) and BCL-2 inhibitor (navitoclax)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: BRAF inhibitor (PLX4720) with BH3-mimetic (navitoclax)
Number of subjects: 17
Study: 24983379

Group type: EXPERIMENTAL
Intervention: Short-term cold exposure (15 min exposure to temperature -10°C, wind 3 m/s, winter clothes)
Number of subjects: 51
Study: 24984785

Group type: EXPERIMENTAL
Intervention: ATX-101 1 mg/cm²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATX-101 2 mg/cm²
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24985410

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100-250 mg bid)
Number of subjects: 4091

Group type: COMPARATOR
Intervention: Oxycodone CR (20-50 mg bid)
Number of subjects: 4091

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4091
Study: 24986245

Group type: EXPERIMENTAL
Intervention: Wide-field endoscopic mucosal resection (WF-EMR)
Number of subjects: 1000
Study: 24986638

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 14 weeks
Number of subjects: 1903

Group type: EXPERIMENTAL
Intervention: Genetic variations in glutamatergic-monoaminergic pathway
Number of subjects: 1903
Study: 24986689

Group type: EXPERIMENTAL
Intervention: High 5-hydroxymethylcytosine (5hmC) levels
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Low 5-hydroxymethylcytosine (5hmC) levels
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Intermediate 5-hydroxymethylcytosine (5hmC) levels
Number of subjects: 206
Study: 24987412

Group type: EXPERIMENTAL
Intervention: Lumbar to sacral nerve rerouting
Number of subjects: 13
Study: 24988120

Group type: EXPERIMENTAL
Intervention: TRV ≥ 3.0 m/sec
Number of subjects: 572

Group type: COMPARATOR
Intervention: TRV < 3.0 m/sec
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: NT-proBNP ≥ 160 pg/mL
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Both TRV ≥ 3.0 m/sec and NT-proBNP ≥ 160 pg/mL
Number of subjects: 572
Study: 24988449

Group type: EXPERIMENTAL
Intervention: GMI 1070
Number of subjects: 15
Study: 24988476

Group type: EXPERIMENTAL
Intervention: Metformin (oral medication)
Number of subjects: 0
Study: 24990396

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid maintenance dose (MD)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Prasugrel 10 mg MD
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid MD
Number of subjects: 512
Study: 24990476

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 26